Format

Send to

Choose Destination
PLoS One. 2017 Aug 14;12(8):e0183191. doi: 10.1371/journal.pone.0183191. eCollection 2017.

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.

Author information

1
Departament de Medicina, Universitat de Barcelona, Barcelona, Spain.
2
CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
3
Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain.
4
Malalties Prevenibles amb vacunes, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.
5
Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain.
6
Hospital Universitari Vall d'Hebron, Barcelona, Spain.
7
Hospital de Nens, Barcelona, Spain.
8
Grup de Recerca en Epidemiologia i Salut Pública, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
9
Departament de Medicina, Universitat Internacional de Catalunya, Barcelona, Spain.

Abstract

BACKGROUND:

The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine. We assessed the vaccination effectiveness (VE) of the PCV13 in preventing invasive pneumococcal disease (IPD) in children aged 7-59 months in a population with suboptimal vaccination coverage of 55%.

METHODS:

The study was carried out in children with IPD admitted to three hospitals in Barcelona (Spain) and controls matched by hospital, age, sex, date of hospitalization and underlying disease. Information on the vaccination status was obtained from written medical records. Conditional logistic regression was made to estimate the adjusted VE and 95% confidence intervals (CI).

RESULTS:

169 cases and 645 controls were included. The overall VE of ≥1 doses of PCV13 in preventing IPD due to vaccine serotypes was 75.8% (95% CI, 54.1-87.2) and 90% (95% CI, 63.9-97.2) when ≥2 doses before 12 months, two doses on or after 12 months or one dose on or after 24 months, were administered. The VE of ≥1 doses was 89% (95% CI, 42.7-97.9) against serotype 1 and 86.0% (95% CI, 51.2-99.7) against serotype 19A. Serotype 3 showed a non-statistically significant effectiveness (25.9%; 95% CI, -65.3 to 66.8).

CONCLUSIONS:

The effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7-59 months was good and, except for serotype 3, the effectiveness of ≥1 doses against the most frequent PCV13 serotypes causing IPD was high when considered individually.

PMID:
28806737
PMCID:
PMC5555701
DOI:
10.1371/journal.pone.0183191
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center